Navigation Links
Dyadic International To Present At World Biofuels Markets
Date:3/4/2013

JUPITER, Fla., March 4, 2013 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical and industrial enzyme industries, announced today that its President and CEO, Mark Emalfarb , will be making a presentation at the World Biofuels Markets exhibition at the Beurs-World Trade Center in Rotterdam, The Netherlands during its Advanced Biofuels Session: Transformative Technologies, at 4:00 p.m. local time on March 13, 2013.

(Logo:  http://photos.prnewswire.com/prnh/20110621/CL06708LOGO )

All attendees of the World Biofuels Markets are welcome to visit Dyadic's stand located at Booth #E506 where Dyadic's leading scientists will be available to discuss specific applications of Dyadic's AlternaFuel® CMAX™ biofuels enzymes.

The World Biofuels Markets is Europe's largest biofuels congress and exhibition and one of the industry's premier events, supporting the world's development and search for alternative energy sources.

About Dyadic

Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical and industrial enzyme industries. Please visit Dyadic's website at www.dyadic.com.

Cautionary Statement for Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.


'/>"/>
SOURCE Dyadic International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Dyadic International To Announce Year-End 2012 Financial Results And Host Conference Call On Thursday, March 7, 2013
2. Dyadic International Upgraded By OTC Markets To "Current Information" Tier
3. 12th U.S. Patent Issued To Dyadic International
4. Dyadic International Reports 2012 Third Quarter Financial Results
5. Dyadic Netherlands To Develop Baking Enzymes For EU-Funded Research Project
6. Dyadic International to Announce Second Quarter 2012 Financial Results and Host Conference Call on Monday, August 13, 2012
7. Dyadic Demonstrates Industry-leading Biofuels Enzyme Performance
8. Dyadic International To Release First Quarter 2012 Financial Results And Host Conference Call
9. Dyadic International Launches FibreZyme® G5000 High Performance Powder Pulp and Paper Enzyme in Booth #1065 at Tissue World Americas Conference
10. Dyadic International Partners with Leading Provider of Nutritional Ingredient Solutions for Production of Food Enzymes
11. BioHealth Innovation, Inc. President & CEO Richard Bendis to Present at SXSW 2013 & 2013 BIO International Convention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Raleigh, NC (PRWEB) , ... June 27, 2016 ... ... a mission to bring innovative medical technologies, services and solutions to the healthcare ... development and implementation of various distribution, manufacturing, sales and marketing strategies that are ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
(Date:6/23/2016)... 23, 2016  The Prostate Cancer Foundation (PCF) is pleased to ... faster cures for prostate cancer. Members of the Class of 2016 were selected ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:6/2/2016)... YORK , June 2, 2016   The Weather ... is announcing Watson Ads, an industry-first capability in which consumers ... by being able to ask questions via voice or text ... Marketers have long sought ... the consumer, that can be personal, relevant and valuable; and ...
(Date:6/1/2016)... Favorable Government Initiatives Coupled With ... Identification to Boost Global Biometrics System Market Through 2021  ... report, " Global Biometrics Market By Type, By ... 2011 - 2021", the global biometrics market is projected ... of growing security concerns across various end use sectors ...
(Date:5/20/2016)... -- VoiceIt is excited to announce its new marketing ... working together, VoiceIt and VoicePass will offer an ... slightly different approaches to voice biometrics, collaboration between ... Both companies ... "This marketing and technology partnership allows VoiceIt ...
Breaking Biology News(10 mins):